Slowing the Inevitable: How Early Antibody Therapy Is Transforming Alzheimer’s Care
“Lately, I keep forgetting appointments.” “They keep repeating what they just said.”When memory lapses in a parent become noticeable, families almost...
Search results for "antibody therapy"
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by maintaining kidney function over a...
Losing Weight Despite a Big Appetite? Blame Your Thyroid, Not the Summer Heat
On scorching summer days, it is easy to blame the weather when you sweat excessively, feel drained, or lie awake at...
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment
For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a...
Beyond Seoul: How a Secondary Hospital in Busan Mastered 167 Incompatible Kidney Transplants
When a family member steps forward to donate a kidney to a loved one suffering from end-stage renal disease, a blood...
Anchoring the U.S. Supply Chain: GC Green Cross Expands 30-Year Cytiva Partnership to Secure Alyglo Production
GC Green Cross has secured priority access to critical manufacturing consumables to stabilize the production of Alyglo,...
Landmark Biotech Deal: Celltrion Acquires Autoimmune Disease Antibody Tech from Catholic University of Korea
A research team led by Kim Wan-wook at the Catholic University of Korea College of Medicine has successfully...
ABL Bio’s Stomach Cancer Drug Shows Promise in Once 'Untreatable' Patients
South Korean platform biotech company ABL Bio announced that development remains firmly on track despite investor...
Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio
Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology...